Lisiane Bajerski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lisiane Bajerski has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ana Maria Bergold
Universidade Federal do Rio Grande do Sul
3 shared publications Carolina L. Dias
Universidade Federal do Rio Grande do Sul, Porto Alegre, Brasil
2 shared publicationsCarolina Lupi Dias
2 shared publications- Pedro Eduardo Fröehlich
Universidade Federal do Rio Grande do Sul (UFRGS)
2 shared publications Rochele Cassanta Rossi
2 shared publicationsAndrea G. Pereira
Universidade Federal do Rio Grande do Sul, Porto Alegre, Brasil
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by FapUNIFESP (SciELO) in Química Nova
- Vol. 36 (1) , 34-39
Stability-indicating comparative methods using mekc and lc for determination of olmesartan medoxomil
- 1 January 2013
- Published by FapUNIFESP (SciELO) in Química Nova
- Vol. 36 (1) , 34-39
Open AccessStability-indicating comparative methods using mekc and lc for determination of olmesartan medoxomil
- 20 February 2011
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 54 (3) , 439-444
Development and validation of discriminating method of dissolution for fosamprenavir tablets based on in vivo data
- 20 February 2011
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 54 (3) , 439-444
Development and validation of discriminating method of dissolution for fosamprenavir tablets based on in vivo data
- 1 January 2011
- Published by Dissolution Technologies in Dissolution Technologies
- Vol. 18 (3) , 47-53
Dissolution Method for Milnacipran Hydrochloride Capsules: Development, Validation, and Study of Changes in Dissolution Rate after Storage
- 1 January 2011
- Published by Dissolution Technologies in Dissolution Technologies
- Vol. 18 (3) , 47-53
Dissolution Method for Milnacipran Hydrochloride Capsules: Development, Validation, and Study of Changes in Dissolution Rate after Storage
- 7 April 2010
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 11 (2) , 637-644
Development and Validation of a Discriminating In Vitro Dissolution Method for a Poorly Soluble Drug, Olmesartan Medoxomil: Comparison Between Commercial Tablets
A dissolution test for tablets containing 40 mg of olmesartan medoxomil (OLM) was developed and validated using both LC-UV and UV methods. After evaluation of the sink condition, dissolution medium, and stability of the drug, the method was validated using USP apparatus 2, 50 rpm rotation speed, and 900 ml of deaerated H2O + 0.5% sodium lauryl sulfate (w/v) at pH 6.8 (adjusted with 18% phosphoric acid) as the dissolution medium. The model-independent method using difference factor (f 1) and similarity factor (f 2), model-dependent method, and dissolution efficiency were employed to compare dissolution profiles. The kinetic parameters of drug release were also investigated. The obtained results provided adequate dissolution profiles. The developed dissolution test was validated according to international guidelines. Since there is no monograph for this drug in tablets, the dissolution method presented here can be used as a quality control test for OLM in this dosage form, especially in a batch to batch evaluation.
- 7 April 2010
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 11 (2) , 637-644
Development and Validation of a Discriminating In Vitro Dissolution Method for a Poorly Soluble Drug, Olmesartan Medoxomil: Comparison Between Commercial Tablets
A dissolution test for tablets containing 40 mg of olmesartan medoxomil (OLM) was developed and validated using both LC-UV and UV methods. After evaluation of the sink condition, dissolution medium, and stability of the drug, the method was validated using USP apparatus 2, 50 rpm rotation speed, and 900 ml of deaerated H2O + 0.5% sodium lauryl sulfate (w/v) at pH 6.8 (adjusted with 18% phosphoric acid) as the dissolution medium. The model-independent method using difference factor (f 1) and similarity factor (f 2), model-dependent method, and dissolution efficiency were employed to compare dissolution profiles. The kinetic parameters of drug release were also investigated. The obtained results provided adequate dissolution profiles. The developed dissolution test was validated according to international guidelines. Since there is no monograph for this drug in tablets, the dissolution method presented here can be used as a quality control test for OLM in this dosage form, especially in a batch to batch evaluation.
- Open Access
- 1 January 2010
- Published by FapUNIFESP (SciELO) in Química Nova
- Vol. 33 (1) , 114-118
Determination of cetirizine in tablets and compounded capsules: comparative study between CE and HPLC
A capillary electrophoresis (CE) method was developed and validated for determination of cetirizine dihydrochloride in tablets and compounded capsules. The electrophoretic separation was performed in an uncoated fused-silica capillary (40 cm x 50 μm i.d.) using 20 mmol L-1 sodium tetraborate buffer (pH 9.3) as background electrolyte, a hydrodinamic sample injection at 50 mBar for 5 s, 20 KV applied voltage at 25 °C, and detection at 232 nm. The proposed method was compared with the high performance liquid chromatographic (HPLC) method previously validated for this drug, and statistical analysis showed no significant difference between the techniques.
- 1 January 2010
- Published by FapUNIFESP (SciELO) in Química Nova
- Vol. 33 (1) , 114-118
Open AccessDetermination of cetirizine in tablets and compounded capsules: comparative study between CE and HPLC
A capillary electrophoresis (CE) method was developed and validated for determination of cetirizine dihydrochloride in tablets and compounded capsules. The electrophoretic separation was performed in an uncoated fused-silica capillary (40 cm x 50 μm i.d.) using 20 mmol L-1 sodium tetraborate buffer (pH 9.3) as background electrolyte, a hydrodinamic sample injection at 50 mBar for 5 s, 20 KV applied voltage at 25 °C, and detection at 232 nm. The proposed method was compared with the high performance liquid chromatographic (HPLC) method previously validated for this drug, and statistical analysis showed no significant difference between the techniques.